Table of Contents
- Trial overview
- Multiple myeloma studies
- Autoimmune disease study
- Long-term follow-up research
- Key endpoints and what they mean
- Who can participate
- Study phases and what they tell us
Trial overview
The trial data show several studies of Idecabtagene Vicleucel in different settings, mainly for multiple myeloma and one study in autoimmune disease.[1][2][4][6]
These studies include Phase 1, Phase 2, Phase 3, and Phase 4 research, so they cover early safety testing, treatment comparison, and long-term follow-up.[1][2][3][4][5][6]
Multiple myeloma studies
Most of the listed trials focus on multiple myeloma, a cancer of plasma cells, including people with relapsed and refractory disease.[1][4]
One Phase 3 study compared bb2121, which is the study name used in the record, with standard regimens in subjects who had relapsed and refractory multiple myeloma after at least two prior therapies, including an immunomodulatory drug and a proteasome inhibitor.[1]
That study was completed and included 386 participants.[1]
The main endpoint was progression-free survival (PFS), which means the time before the disease gets worse.[1]
Another completed Phase 2 study looked at people with relapsed and refractory multiple myeloma, as well as some people with newly diagnosed disease who had a suboptimal response after autologous stem cell transplant.[4]
This study enrolled 248 participants and measured overall response rate (ORR) and complete response (CR) rate in different cohorts, which are groups of participants inside the study.[4]
A Phase 3 study in newly diagnosed multiple myeloma with suboptimal response after autologous stem cell transplant compares Idecabtagene Vicleucel plus lenalidomide maintenance with lenalidomide maintenance alone.[6]
That study is authorised and has 681 planned participants.[6]
Its main endpoint is progression-free survival, so it is asking whether the combination keeps the disease under control longer than maintenance treatment alone.[6]
Autoimmune disease study
One authorised Phase 1 study is testing anti-BCMA CAR T cell therapy, identified in the brief summary as ide-cel, in people with progressive systemic autoimmune disease resistant to B cell depletion.[2]
The autoimmune diseases named in the brief summary are SLE, IIM, SSc, and PSS, which are abbreviations for systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, and primary Sjögren syndrome.[2]
This is a small early study with 15 participants, and its main goal is safety.[2]
The primary outcome measures serious side effects such as severe cytokine release syndrome, severe immune effector cell-associated neurotoxicity syndrome, severe organ toxicity, and other important immune-related problems.[2]
Long-term follow-up research
The Phase 4 long-term follow-up protocol enrolls adult and pediatric participants who previously received at least one genetically modified T-cell infusion in a Celgene-sponsored study, including Idecabtagene Vicleucel.[3]
This study is very large, with 1,410 participants, and it follows people for up to 15 years after the last infusion.[3]
The study looks at delayed adverse events, persistence of the gene-modified T-cell product, vector integration sites, replication competent lentivirus, overall survival, and disease progression in participants who entered the study with a malignancy.[3]
For children and teenagers, the study also tracks physical growth and sexual maturity until Tanner Stage 5, which is a measure of pubertal development.[3]
Key endpoints and what they mean
Endpoints are the main results a trial wants to measure.[1][2][3][4][6]
- Progression-free survival (PFS) means how long the disease stays stable before it gets worse.[1][6]
- Overall response rate (ORR) means how many participants had a meaningful improvement in their disease.[4]
- Complete response (CR) means no clear signs of disease were found after treatment.[4]
- Adverse events are unwanted medical problems that happen during a study.[2][3]
- Cytokine release syndrome (CRS) is a strong immune reaction that can happen after cell therapy.[2]
- Immune effector cell-associated neurotoxicity syndrome (ICANS) is a nerve and brain side effect that can affect thinking, speech, or alertness.[2][5]
- Overall survival means how long participants live after treatment.[3]
- Persistence means how long the modified cells stay in the body.[3]
Who can participate
Based on the trial records, the main participants are adults with relapsed and refractory multiple myeloma, adults with newly diagnosed multiple myeloma after autologous stem cell transplant, and some people with progressive systemic autoimmune disease resistant to B cell depletion.[1][2][4][6]
The long-term follow-up study also includes pediatric participants who had earlier gene-modified T-cell treatment in a previous study.[3]
Some studies require prior treatments, such as at least two earlier therapies for relapsed and refractory multiple myeloma, including an immunomodulatory compound and a proteasome inhibitor.[1]
Other studies focus on people who still have active disease after transplant or who did not respond well enough to earlier treatment.[4][6]
Study phases and what they tell us
Phase 1 studies are early studies that mainly check safety and tolerability.[2][5]
Phase 2 studies usually look more closely at whether the treatment works.[4]
Phase 3 studies compare the new approach with standard treatment or another control group in larger groups of patients.[1][6]
Phase 4 studies follow patients after earlier research is done and can show delayed or long-term effects.[3]
In this set of trials, the phase mix shows that Idecabtagene Vicleucel is being studied both as a treatment option and as a therapy that needs long-term safety tracking.[1][2][3][4][6]
